Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Yoshihiko Sakata(Saiseikai Kumamoto Hospital), Go Saito(Chiba University), Shinya Sakata(Kumamoto University Hospital), Teppei Yamaguchi(Aichi Cancer Center), Motohiro Tamiya(Osaka International Cancer Institute), Hidekazu Suzuki(Osaka Prefectural Medical Center), Ryota Shibaki(Wakayama Medical University), Asuka Okada(Osaka City General Hospital), Toshihide Yokoyama(Kurashiki Central Hospital), Hirotaka Matsumoto(Hyogo Prefectural Amagasaki General Medical Center), Taiichiro Otsuki(Hyogo University), Yuki Sato(Kobe City Medical Center General Hospital), Junji Uchida(Toneyama National Hospital), Yoko Tsukita(Tohoku University), Megumi Inaba(Kumamoto City Hospital), Hideki Ikeda(Chiba University Hospital), Daisuke Arai(Saiseikai Utsunomiya hospital), Hirotaka Maruyama(Japan Organization of Occupational Health and Safety), Satoshi Hara(Itami City Hospital), Shinsuke Tsumura(Kumamoto Medical Center), Jun Morinaga(Kumamoto University Hospital), Takuro Sakagami(Kumamoto University Hospital)
Cited by 4
Abstract
Related Papers
No related papers found
Powered by citation graph analysis